Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users can adjunctly use sugarBEAT when calibrated with a finger-stick glucose reading,” reads a recent article. SugarBEAT offers advantages such as the fact that users no longer need to draw blood samples or prick their fingers and that a person can easily wear the disposable adhesive CGM skin patch — connected to a rechargeable transmitter with a smartphone app displaying glucose readings. Existing CGM devices must be implanted under the skin. Nemaura’s already launched products include digital solutions for weight loss and potential reversal of type 2 diabetes and glucose monitoring solutions for diabetes prevention and reversal. Other products include continuous lactate monitoring for athletic performance (non-medical) and in disease state (medical), and continuous temperature monitoring for detection of viral infection and disease propagation.
To view the full article, visit https://ibn.fm/P1oj7
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
